American Journal of Cardiology
Volume 103, Issue 3 , Pages 381-386, 1 February 2009

Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort)

  • Virginie Gardette, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
  • ,
  • Vanina Bongard, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
  • ,
  • Jean Dallongeville, MD

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, Lille, France
  • ,
  • Dominique Arveiler, MD

      Affiliations

    • Department of Epidemiology and Public Health, Louis Pasteur University, Strasbourg, France
  • ,
  • Annie Bingham, MA

      Affiliations

    • INSERM U909, Paul Brousse Hospital, Villejuif, France
  • ,
  • Jean-Bernard Ruidavets, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
  • ,
  • Philippe Amouyel, MD

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, Lille, France
  • ,
  • Bernadette Haas, MD

      Affiliations

    • Department of Epidemiology and Public Health, Louis Pasteur University, Strasbourg, France
  • ,
  • Pierre Ducimetière, PhD

      Affiliations

    • INSERM U909, Paul Brousse Hospital, Villejuif, France
  • ,
  • Jean Ferrières, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
    • Department of Cardiology, Toulouse-Rangueil University Hospital, Toulouse, France
    • Corresponding Author InformationCorresponding author: Tel: +33-561-521-870; fax: +33-561-145-627

Received 12 August 2008; received in revised form 25 September 2008; accepted 25 September 2008. published online 25 November 2008.

Lipid-lowering drugs are one of the most prescribed drugs worldwide. The aim was to compare 10-year all-cause mortality according to initial dyslipidemia status and lipid-lowering drug exposure. The PRIME study was a multicenter population-based prospective cohort study of men recruited in 1991 to 1993, aged 50 to 59 years at baseline, and followed up for 10 years. The 4 groups compared were normolipidemic, untreated dyslipidemic, and dyslipidemic subjects on fibrate or statin therapy. Data were analyzed using multivariate Cox models. The cohort included 7,722 French men (statin group 4.0%, fibrate group 7.9%, untreated dyslipidemic subjects 19.0%, and normolipidemic subjects 69.1%). After 10 years, 4.8% of the sample was lost to follow-up and 416 deaths occurred (cancers 53.1%, cardiovascular diseases 17.1%, and other 29.8%). After adjustment for center, age, educational level, cardiovascular risk factors, lipids, alcohol intake, and history of cardiovascular and severe chronic diseases, hazard ratios (HRs) for all-cause mortality were 0.49 (95% confidence interval [CI] 0.26 to 0.94, p = 0.031) for subjects treated with a statin, 0.65 (95% CI 0.42 to 0.99, p = 0.046) for those on fibrate therapy, and 0.76 (95% CI 0.56 to 1.03, p = 0.080) for normolipidemic men compared with untreated dyslipidemic subjects. In the statin group, HRs for death from cardiovascular disease, cancer, and other causes were 0.55 (p = 0.348), 0.41 (p = 0.067), and 0.68 (p = 0.546) compared with dyslipidemic subjects, respectively. In the fibrate group, HRs were 0.76 (p = 0.499), 0.52 (p = 0.041), and 0.87 (p = 0.746). In conclusion, in this cohort study carried out in a real-life setting, all-cause mortality was significantly lower in dyslipidemic subjects on fibrate or statin therapy than in untreated dyslipidemic patients. No excess risk of noncardiovascular death was observed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9149(08)01709-8

doi:10.1016/j.amjcard.2008.09.092

American Journal of Cardiology
Volume 103, Issue 3 , Pages 381-386, 1 February 2009